Halozyme Therapeutics. has been granted a patent for modified PH20 hyaluronidase polypeptides that demonstrate enhanced stability and activity. The patent includes specific claims regarding amino acid modifications and sequence identity related to the unmodified PH20 polypeptide. GlobalData’s report on Halozyme Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Halozyme Therapeutics, was a key innovation area identified from patents. Halozyme Therapeutics's grant share as of June 2024 was 52%. Grant share is based on the ratio of number of grants to total number of patents.
Modified ph20 hyaluronidase polypeptides with enhanced stability and activity
The patent US12037618B2 describes a modified PH20 polypeptide characterized by specific amino acid modifications compared to an unmodified PH20 polypeptide. The claims detail that the unmodified polypeptide can be derived from several specified amino acid sequences (SEQ ID NO: 3, 7, and 32-66) and that the modifications may include replacements, deletions, or insertions, particularly at position 309. The modified polypeptide must maintain at least 91% sequence identity to the original sequences, with some claims specifying a higher threshold of 95%. Notably, the modified PH20 polypeptide exhibits increased stability under denaturing conditions and enhanced hyaluronidase activity, which may have implications for therapeutic applications.
Additionally, the patent outlines various forms of the modified PH20 polypeptide, including those that are glycosylated or conjugated to polymers such as dextran or polyethylene glycol (PEG). The claims also encompass pharmaceutical compositions containing the modified polypeptide, which may include a range of therapeutically active agents, such as proteins, nucleic acids, or small molecules. Methods for treating hyaluronan-associated diseases, including inflammatory conditions and tumors, are also described, emphasizing the potential of the modified PH20 polypeptide to improve the delivery of therapeutic agents. The comprehensive nature of the claims suggests a broad applicability of the modified polypeptide in medical treatments, particularly in enhancing therapeutic efficacy and stability.
To know more about GlobalData’s detailed insights on Halozyme Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
